Terms: = Germ cell tumor AND PSA AND Treatment
59 results:
1. Clinical, pathologic, and molecular features of amphicrine prostate cancer.
Graham LS; Haffner MC; Sayar E; Gawne A; Schweizer MT; Pritchard CC; Coleman I; Nelson PS; Yu EY
Prostate; 2023 May; 83(7):641-648. PubMed ID: 36779357
[TBL] [Abstract] [Full Text] [Related]
2. Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
Kemble J; Kwon ED; Karnes RJ
Expert Rev Anticancer Ther; 2023 Feb; 23(2):177-185. PubMed ID: 36698089
[TBL] [Abstract] [Full Text] [Related]
3. Economic Evaluation of Three BRAF + MEK Inhibitors for the treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective.
Halloush S; Alkhatib NS; Almutairi AR; Calamia M; Halawah H; Obeng-Kusi M; Hoyle M; Rashdan O; Koeller J; Abraham I
Ann Pharmacother; 2023 Sep; 57(9):1016-1024. PubMed ID: 36639851
[TBL] [Abstract] [Full Text] [Related]
4. Polysialic Acid Sustains the Hypoxia-Induced Migration and Undifferentiated State of Human Glioblastoma cells.
Rosa P; Scibetta S; Pepe G; Mangino G; Capocci L; Moons SJ; Boltje TJ; Fazi F; Petrozza V; Di Pardo A; Maglione V; Calogero A
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076963
[TBL] [Abstract] [Full Text] [Related]
5. A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.
Brown LC; Halabi S; Somarelli JA; Humeniuk M; Wu Y; Oyekunle T; Howard L; Huang J; Anand M; Davies C; Patel P; Staats J; Weinhold KJ; Harrison MR; Zhang T; George DJ; Armstrong AJ
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):762-769. PubMed ID: 35292724
[TBL] [Abstract] [Full Text] [Related]
6. Prostatic Schwannoma Presenting with Prostate-specific Antigen Elevation: A Case Report.
Lai BCH; Shih HJ; Syu SH; Lin KH
Yale J Biol Med; 2021 Dec; 94(4):609-612. PubMed ID: 34970099
[No Abstract] [Full Text] [Related]
7. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
[TBL] [Abstract] [Full Text] [Related]
8. Clinicopathological and genetic analyses of small cell neuroendocrine carcinoma of the prostate: Histological features for accurate diagnosis and toward future novel therapies.
Ida A; Okubo Y; Kasajima R; Washimi K; Sato S; Yoshioka E; Osaka K; Suzuki T; Yamamoto Y; Yokose T; Kishida T; Miyagi Y
Pathol Res Pract; 2022 Jan; 229():153731. PubMed ID: 34952423
[TBL] [Abstract] [Full Text] [Related]
9. [Diagnosis and treatment of small cell neuroendocrine carcinoma of the prostate].
Zhang M; Shi W; Zhang QW; Wang W; Li QY
Zhonghua Nan Ke Xue; 2021 Mar; 27(3):219-225. PubMed ID: 34914303
[TBL] [Abstract] [Full Text] [Related]
10. PAQR6 Upregulation Is Associated with AR Signaling and Unfavorite Prognosis in Prostate Cancers.
Yang M; Li JC; Tao C; Wu S; Liu B; Shu Q; Li B; Zhu R
Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572596
[TBL] [Abstract] [Full Text] [Related]
11. Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands.
Hagendijk ME; van der Schans S; Boersma C; Postma MJ; van der Pol S
Eur J Health Econ; 2021 Aug; 22(6):991-999. PubMed ID: 33829344
[TBL] [Abstract] [Full Text] [Related]
12. Therapeutic effect of thalidomide combined with temozolomide and three-dimensional conformal radiotherapy for patients with high-grade gliomas after operation.
Sui L; Li Y; Xu Z; Shen X
J BUON; 2021; 26(1):2608-2615. PubMed ID: 33721435
[TBL] [Abstract] [Full Text] [Related]
13. [Pathological features of primary extragonadal germ cell tumor of the prostate with small round blue cell morphology].
Gan HL; Wang QF
Zhonghua Bing Li Xue Za Zhi; 2021 Feb; 50(2):108-113. PubMed ID: 33535304
[No Abstract] [Full Text] [Related]
14. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract] [Full Text] [Related]
15. Ubiquinone-BODIPY nanoparticles for tumor redox-responsive fluorescence imaging and photodynamic activity.
Hwang B; Kim TI; Kim H; Jeon S; Choi Y; Kim Y
J Mater Chem B; 2021 Jan; 9(3):824-831. PubMed ID: 33338098
[TBL] [Abstract] [Full Text] [Related]
16. Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report.
Williams SG; Aw Yeang HX; Mitchell C; Caramia F; Byrne DJ; Fox SB; Haupt S; Schittenhelm RB; Neeson PJ; Haupt Y; Keam SP
BMC Urol; 2020 Oct; 20(1):171. PubMed ID: 33115461
[TBL] [Abstract] [Full Text] [Related]
17. Conditionally Reprogrammed cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development.
Ci X; Hao J; Dong X; Xue H; Wu R; Choi SYC; Haegert AM; Collins CC; Liu X; Lin D; Wang Y
Cells; 2020 Jun; 9(6):. PubMed ID: 32512818
[TBL] [Abstract] [Full Text] [Related]
18. Clinical features of neuroendocrine prostate cancer.
Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
[TBL] [Abstract] [Full Text] [Related]
19. Patterns of care and outcomes in small cell carcinoma of the prostate: A national cancer database analysis.
Metzger AL; Abel S; Wegner RE; Fuhrer R; Mao S; Miller R; Beriwal S; Horne ZD
Prostate; 2019 Sep; 79(12):1457-1461. PubMed ID: 31294484
[TBL] [Abstract] [Full Text] [Related]
20. Asynchronous tumour quadruplicity: rectosigmoid adenocarcinoma, renal cell carcinoma, prostate adenocarcinoma and neuroendocrine small-cell lung cancer - a case report.
Adwan R; Prošvic P; Prošvicová J; Tomšová M
Rozhl Chir; 2018; 97(9):427-431. PubMed ID: 30470124
[TBL] [Abstract] [Full Text] [Related]
[Next]
